Document is current
Any future updates will be listed below
-
Authors
Boux, Fabien https://orcid.org/0000-0002-3417-1313
Mercier, Alexis
Talba, Daniela
Giraud, Jean-Yves
Dufort, Sandrine
Seddik, Khalide
Grand, Sylvie
Gataleta, Mélanie
Leboucher, Alexandre
Pietras, Johan
De Beaumont, Olivier
Le Duc, Géraldine
Verry, Camille
- License Information
-
More Information
Article History
Received: 19 December 2025
Accepted: 10 February 2026
First Online: 4 April 2026
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki (as amended in 2013 in Fortaleza). Approval was granted by the Comité de Protection des Personnes (CPP) and the National Agency for Safety of Drugs and Health Products (ANSM). The study was conducted in strict compliance with the recommendations for Good Clinical Practice (GCP, ICHE6). Clinical trial registration: NCT03818386.
: Written informed consent was obtained from all individual participants included in the study.
: Financial interests: Géraldine Le Duc, Sandrine Dufort and Camille Verry disclose patent No. PCT/FR2019/000124 protecting AGuIX nanoparticles described in this publication. Géraldine Le Duc, Sandrine Dufort and Olivier de Beaumont own shares in NH TherAguix (Meylan, France), which develops AGuIX nanoparticles. Fabien Boux, Daniela Talba, Sandrine Dufort, Khalide Seddik, Olivier de Beaumont and Géraldine Le Duc are employees at NH TherAguix. The remaining authors declare no competing financial interests.
